EZH2 and neoplasm: Consistent with the notion that Foxc1 was a target of transcriptional silencing by Ezh2, immunofluorescence revealed that Ezh2 and Foxc1 did not co-localize in endpoint Tet-ON PyVmT tumours (Fig. 3g).